Celgene Reports Third Quarter 2017 Operating and Financial Results
Updating 2017 guidance and financial targets for 2020 Data from multiple next generation growth drivers being presented at 14 major global medical meetings in Q4 including ECTRIMS UEGW and ASH Celgene...
View ArticleSome GI disorders get disproportionate share of U.S. research funding
Reuters Health Gastrointestinal GI disorders such as Crohns disease and Barretts esophagus get a bigger slice of U.S. public research funding than other GI conditions that affect many more Americans...
View ArticleGlobal Budesonide Market Analysis 20112017 and Forecast 20182023 Report...
SnapshotBudesonide BUD sold under the brand name Pulmicort among others is a steroid medication. It is available as an inhaler pill and nasal spray.The inhaled form is used in the long term management...
View Article180 Medical Named One of the Best Companies to Work in Oklahoma
This is the eighth time the medical supplies company has received the honor.OKLAHOMA CITY PRWEB October 27 2017 180 Medical one of America&39;s largest home delivery providers of sterileuse...
View ArticleFrench Biotechs Crohns Candidate Glides Through Phase I
Enterome has completed a Phase I study testing its leading Crohn&8217;s disease candidate which could become one of the first microbiome therapies on the market. French biotech EnteromeÂhas...
View ArticleInnovent Biologics Inc Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryInnovent Biologics Inc Innovent Biologics is a biopharmaceutical company that discovers develops and manufactures monoclonal antibodies. The company's product portfolio comprise monoclonal...
View ArticleChanging our outlook on psoriasis from the inside out.
Today's guest post comes from Mariana Guerreiro Lilly International Corporate Affairs Rheumatology & Dermatology Psoriasis is much more than what can be seen on the outside.Living with...
View ArticleOne Year Maintenance and Switching Data in Patients with Crohns Disease...
Efficacy and safety profiles including immunogenicity were observed to be comparable between patients maintained on INFLECTRA or REMICADE and those switched to INFLECTRA from REMICADEÂ1 Read more...
View ArticleOne Year Maintenance and Switching Data in Patients with Crohns Disease...
Efficacy and safety profiles including immunogenicity were observed to be comparable between patients maintained on INFLECTRA or REMICADE and those switched to INFLECTRA from REMICADEÂ1 New data show...
View ArticleCelltrion Healthcare Present 1year Results for CTP13 Biosimilar Infliximab...
CTP13 shown to be comparable in efficacy and safety to reference infliximab in switched inflammatory bowel disease patients CTP13 shown to be welltolerated in subcutaneous form BARCELONA...
View ArticleCelltrion Healthcare announces results from phase III CTP13 switching trial...
Today at the 25th United European Gastroenterology Week Congress Celltrion Healthcare presented data from the phase III randomized controlled switching trial comparing CTP13 and reference infliximab.
View ArticleSwitching Crohn's patients to biosimilar Inflectra from Remicade is safe and...
Pfizer has released new data on its Crohns disease CD treatment Inflectra infliximab CTP13 which indicate that switching patients to the drug from Remicade infliximab is comparably safe and effective...
View ArticleFDA Grants Cosmo Pharmaceuticals Both QIDP and Fast Track Designations for...
Upon FDA Approval Aries Pharmaceuticals Inc. to Lead U.S. Commercial Efforts Cosmo Pharmaceuticals N.V. SIX COPN today announced that the U.S. Food and Drug Administration FDA has granted both...
View ArticleSetPoint Medical Presents Early Data Showing Bioelectronic Medicine...
Data Presented at ECTRIMSACTRIMS Multiple Sclerosis Meeting in Paris SetPoint Medical a clinicalstage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases...
View ArticleOne Year Maintenance and Switching Data in Patients with Crohns Disease...
NEW YORK&8211;BUSINESS WIRE&8211;New data show that switching patients with Crohns disease CD to INFLECTRA infliximab CTP13 from REMICADE infliximab led to comparable efficacy safety and...
View ArticleJanssens Stelara shows improvement in Crohns symptoms within one week new...
Janssen has unveiled new data on Stelara ustekinumab in the treatment of patients with moderately to severely active Crohn's disease at the 25th United European Gastroenterology Week. The findings...
View ArticleQueens Medical Associates Hosts Breast Cancer Information Session
Interactive discussion sheds light on breast cancer treatment and survivorshipQueens NY PRWEB October 30 2017 Queens Medical Associates a leading oncology and hematology practice and infusion center...
View ArticleComment Targeting Crohn's disease
There are many similarities between Crohn's disease and rheumatoid arthritis such as in pathogenesis; in disconnect between symptoms biological inflammatory activity and structural damage; and in...
View ArticleArticles Effect of tight control management on Crohn's disease CALM a...
CALM is the first study to show that timely escalation with an antitumour necrosis factor therapy on the basis of clinical symptoms combined with biomarkers in patients with early Crohn's disease...
View ArticleRedHill Biopharma Ltd RDHL Pharmaceuticals Healthcare Deals and Alliances...
SummaryRedHill Biopharma Ltd RedHill is a biopharmaceutical company that develops and commercializes small molecule therapeutics in the areas of gastroenterology oncology and inflammation. The...
View Article